Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M93,291Revenue $M25,711Net Margin (%)9.9Z-Score1.6
Enterprise Value $M98,498EPS $2.0Operating Margin %14.4F-Score4
P/E(ttm))22.4Cash Flow Per Share $9.7Pre-tax Margin (%)12.7Higher ROA y-yN
Price/Book2.210-y EBITDA Growth Rate %7.6Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %-9.0Current Ratio0.9Lower Leverage y-yY
Price/Cash Flow5.0y-y EBITDA Growth Rate %-22.5ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.8Insider Buy (3m)0ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %172Shares Outstanding M1,263ROI % (ttm)12.6Gross Margin Increase y-yN

Gurus Latest Trades with AZN

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AZNJohn Hussman 2014-03-31 Add0.96%$58.51 - $68.15
($64.29)
$ 73.8915%Add 714.29%228,000
AZNDavid Dreman 2014-03-31 Add0.14%$58.51 - $68.38
($64.41)
$ 73.8915%Add 26.61%135,439
AZNJoel Greenblatt 2014-03-31 Buy 0.09%$58.51 - $68.38
($64.41)
$ 73.8915%New holding, 95518 sh.95,518
AZNCharles Brandes 2014-03-31 Reduce-0.84%$58.51 - $68.15
($64.29)
$ 73.8915%Reduce -46.73%1,333,894
AZNDavid Dreman 2013-12-31 Reduce-0.34%$49.72 - $59.5
($54.28)
$ 73.8936%Reduce -40.32%106,975
AZNJohn Hussman 2013-12-31 Reduce-0.11%$49.72 - $59.5
($54.28)
$ 73.8936%Reduce -58.82%28,000
AZNCharles Brandes 2013-09-30 Add0.12%$47.88 - $52.08
($50.24)
$ 73.8947%Add 7.92%2,381,040
AZNJohn Hussman 2013-09-30 Reduce-0.66%$47.88 - $52.08
($50.24)
$ 73.8947%Reduce -81.87%68,000
AZNJohn Hussman 2013-06-30 Reduce-1.02%$47.22 - $53.01
($50.92)
$ 73.8945%Reduce -59.76%375,000
AZNJoel Greenblatt 2013-06-30 Sold Out -0.24%$47.22 - $53.01
($50.92)
$ 73.8945%Sold Out0
AZNJohn Hussman 2013-03-31 Reduce-0.74%$44.67 - $50.06
($47.4)
$ 73.8956%Reduce -38.8%932,000
AZNCharles Brandes 2012-12-31 Buy 1.2%$44.34 - $48.9
($46.77)
$ 73.8958%New holding, 2188735 sh.2,188,735
AZNJohn Hussman 2012-12-31 Reduce-0.56%$44.34 - $48.9
($46.77)
$ 73.8958%Reduce -24.49%1,523,000
AZNDavid Dreman 2012-12-31 Reduce-0.2%$44.34 - $48.9
($46.77)
$ 73.8958%Reduce -52.4%152,504
AZNJoel Greenblatt 2012-12-31 Reduce-0.12%$44.34 - $48.9
($46.77)
$ 73.8958%Reduce -31.34%83,972
AZNJoel Greenblatt 2012-09-30 Add0.12%$44.91 - $48.35
($46.83)
$ 73.8958%Add 42.7%122,294
AZNCharles Brandes 2012-09-30 Sold Out -1.2%$44.91 - $48.35
($46.83)
$ 73.8958%Sold Out0
AZNDavid Dreman 2012-09-30 Reduce-0.11%$44.91 - $48.35
($46.83)
$ 73.8958%Reduce -24.31%320,376
AZNJoel Greenblatt 2012-03-31 Add0.12%$44.18 - $48.58
($42.78)
$ 73.8973%Add 66.8%74,557
AZNJoel Greenblatt 2011-12-31 Buy 0.25%$42.53 - $49.89
($46.11)
$ 73.8960%New holding, 44699 sh.44,699
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AZN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AZN Joel Greenblatt 2014-03-3195,5180.010.09New Buy
AZN John Hussman 2014-03-31228,0000.021.1+714.29%
AZN David Dreman 2014-03-31135,4390.010.68+26.61%
AZN Charles Brandes 2014-03-311,333,8940.111.1-46.73%
Premium Most recent portfolio changes are included for Premium Members only!


AZN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about AZN :

    Quarterly/Annual Reports about AZN:

      News about AZN:

      Articles On GuruFocus.com
      I Believe AstraZeneca Is Fairly Valued Jul 16 2014 
      A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
      Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 
      Abbott Capturing Incremental Market Share Mar 18 2014 
      Abbvie's Humira Continues to be a Powerful Catalyst for Growth Mar 18 2014 
      10 British Stocks to Consider Feb 20 2014 
      Bristol-Myers: Don’t Let This One Get Away Jan 15 2014 
      AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 
      Profits Are Good, Cures Are Better: The Pharmaceutical Industry Oct 08 2013 


      More From Other Websites
      Pfizer earnings drop less than expected Jul 29 2014
      "Do Drug Companies Make Drugs, Or Money?" Jul 29 2014
      Merck 2Q profit more than doubles Jul 29 2014
      Merck 2Q profit more than doubles Jul 29 2014
      [video] Big pharma tax attack Jul 29 2014
      [video] Big pharma by the numbers Jul 29 2014
      Drugmakers Merck, Pfizer Eke Out Profit Hikes Jul 29 2014
      Novo Nordisk Diabetes Drug Xultophy Gets Positive CHMP View Jul 29 2014
      Pfizer posts earnings of 58 cents a share vs. 57 cents estimate Jul 29 2014
      Story Stocks from Briefing.com Jul 29 2014
      US tries to ban some 'inversion' firms from government contracts Jul 28 2014
      Why Horizon Pharmaceuticals (HZNP) Is Plummeting Today Jul 28 2014
      Pfizer Dips On BMO Downgrade Jul 28 2014
      Pfizer, Merck, Amgen Near Q2 Earnings Reports Jul 28 2014
      Video: Horizon Pharma Drugs Ditched By Pharmacies; Stock Falls Jul 28 2014
      [video] U.K. Is a Winner in Big Corporate Inversion Deals Jul 28 2014
      3 Things That Say AstraZeneca plc Is A Buy Jul 28 2014
      3 Things That Say AstraZeneca plc Is A Buy Jul 28 2014
      AstraZeneca taps Roche, Qiagen for new blood-based cancer drug tests Jul 28 2014
      QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance... Jul 28 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK
      Email Hide